Digital Content 
NEWS #PharmaBuzz
27 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/27/3050401/0/en/BeyondSpring-Reports-2024-Year-End-Financial-Results-and-Highlights-Key-Clinical-Strategic-Milestones.html
28 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/28/3016236/0/en/BeyondSpring-Announces-35-4-Million-Sale-of-a-Portion-of-Equity-Interest-in-SEED-Therapeutics-to-Advance-Lead-Asset-Plinabulin-to-Anti-Cancer-Registrational-Studies.html
11 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/11/2978241/0/en/BeyondSpring-Presents-Updated-Efficacy-Results-from-a-Phase-2-IIT-Study-of-Triple-IO-Combo-of-Pembrolizumab-plus-Plinabulin-Docetaxel-in-Metastatic-NSCLC-after-Progressing-on-Prior.html
16 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/16/2946478/0/en/BeyondSpring-Presents-Final-Data-Analysis-of-DUBLIN-3-Phase-3-Study-in-2L-3L-EGFR-Wild-type-NSCLC-at-ESMO-Congress-2024.html
10 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/10/2943512/0/en/BeyondSpring-Delivers-Oral-Presentation-at-ISLAC-2024-World-Conference-on-Lung-Cancer-of-its-Lead-Anti-Cancer-Asset-Plinabulin-Showcasing-Positive-Final-Phase-3-Data-in-2L-3L-NSCLC.html
03 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/03/2939501/0/en/BeyondSpring-Announces-Oral-Presentation-at-the-2024-World-Conference-on-Lung-Cancer-and-Two-Poster-Presentations-During-ESMO-Congress-2024-Showcasing-its-Lead-Anti-Cancer-Asset-Pl.html
Share 